Solexa develops a genome analysis system for genome resequencing, gene expression analysis and small RNA analysis.
Solexa engages in developing and commercializing genetic analysis technologies primarily in the United States and the United Kingdom. The company is developing and preparing Solexa Genome Analysis System, which performs DNA sequencing based on its proprietary reversible terminator Sequencing-by-Synthesis, chemistry, and Clonal Single Molecule Array technology. Its platform is designed to support a range of analyses, including whole genome resequencing, gene expression analysis, and small RNA analysis.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Sep 20, 2006 | Post-IPO Equity | $75M | 1 | Azimuth Opportunity | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Azimuth Opportunity | Yes | Post-IPO Equity |